Pharmac’s decision to fund immunotherapy treatment durvalumab (imfinzi) for stage 3 lung cancer is a small step forward. Lung Foundation New Zealand (LFNZ) acknowledges the leaders and clinical advisors at Pharmac and the key people at AstraZeneca for getting durvalumab (imfinzi) across the line. This funding decision also highlights extreme inequities with access to treatments […]

While, Lung Foundation New Zealand (LFNZ) endorses the funding decision and we applaud the efforts of the researchers that dedicate their life to improving health policy, providing lung cancer patients access to more treatment options NOW, will prevent premature death and eliminate inequities.   https://www.rnz.co.nz/news/national/459893/new-research-fund-to-focus-on-inequity-in-lung-cancer-treatment-diagnosis  

We are pleased to share with you Lung Foundation New Zealand’s response to the Pharmac Interim Report. Our response is informed by patients, carers and healthcare professionals associated with our cause. We look forward to contributing to the next phase of the review. 2021 December – Lung Foundation New Zealand response to Interim Report per […]

Help raise awareness about The Symptoms of Lung Cancer by sharing our BREATHE poster LFNZ-BREATHE-Symptoms-Poster Help raise awareness about Lung Cancer Risk Factors by sharing our Risk Factors poster Risk If you know someone that has been diagnosed with lung cancer, share our patient introductory letter C005895-Patient-information-A4-1 Donate to help support our advocacy and patient […]

Lung Foundation New Zealand (LFNZ) filed a submission (link below) to the pharmac review committee and participated in the review forum held at the Ministry of Health in Wellington alongside many other patients groups. LFNZ has collaborated with other advocacy groups to provide the review committee with insights into the experiences of patients and too […]

Lung Foundation New Zealand (LFNZ) really values collaborating with Research Review and we too are pleased to promote the latest issue of Lung Cancer Research Review (per link below). LFNZ acknowledge’s the leadership of Dr Paul Dawkins and Dr Aileen Ludlow, together with the team at Research Review, for their expertise and time to prepare […]

We are thrilled to acknowledge our partnership with Research Review, which is enabling a greater focus on the; detection, treatment and care of lung cancer in New Zealand. Enclosed is the latest issue of Lung Cancer Research Review, which is published with independent commentary by Dr Paul Dawkins, a very knowledgeable and accomplished specialist who is […]